問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital Hsin-Chu Branch

  • 0

    Total Beds

  • 0

    Total Doctors

Recruiting Trial

98Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

144Cases

2023-09-01 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Terminated3Sites

2021-04-06 - 2026-05-08

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting4Sites

Recruiting6Sites

2020-06-01 - 2026-12-31

Others

Active
CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    注射液

Participate Sites
4Sites

Recruiting4Sites

2022-09-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-07-31 - 2026-05-27

Phase II

Completed
Master Protocol Title: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis ISA Title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis

  • Condition/Disease

    f Adults with Moderate-to-Severe Atopic Dermatitis

  • Test Drug

    N/A

Participate Sites
8Sites

Recruiting8Sites

2019-06-15 - 2025-05-31

Phase III

Completed
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3

  • Condition/Disease

    Plaque Psoriasis

  • Test Drug

    Mirikizumab

Participate Sites
7Sites

Terminated7Sites

2018-04-24 - 2020-01-16

Phase III

Completed
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1

  • Condition/Disease

    Moderate-to-Severe Plaque Psoriasis

  • Test Drug

    Mirikizumab

Participate Sites
7Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2025-06-30 - 2027-07-28

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  • Condition/Disease

    Atopic Hand and Foot Dermatitis

  • Test Drug

    Prefilled Injectable

Participate Sites
7Sites

Recruiting7Sites

2023-05-15 - 2030-04-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2030-12-31

Phase III

Active
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung 、Neoplasm Metastasis

  • Test Drug

    N/A N/A N/A N/A N/A

Participate Sites
17Sites

Recruiting17Sites

1 8 9 10 11 12 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB